Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Direct cell-fate conversion of somatic cells: Toward regenerative medicine and industries

Horisawa K., Suzuki A.

Narrative Review on Cardiovascular Disease, published in Proc Jpn Acad Ser B Phys Biol Sci (2020) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Proc Jpn Acad Ser B Phys Biol Sci (2020)
Reported sample size
—
Source database
Europe PMC
PMID
32281550
PMCID
PMC7247973
DOI
10.2183/pjab.96.012
Citations
27

Abstract (original English)

Cells of multicellular organisms have diverse characteristics despite having the same genetic identity. The distinctive phenotype of each cell is determined by molecular mechanisms such as epigenetic changes that occur throughout the lifetime of an individual. Recently, technologies that enable modification of the fate of somatic cells have been developed, and the number of studies using these technologies has increased drastically in the last decade. Various cell types, including neuronal cells, cardiomyocytes, and hepatocytes, have been generated using these technologies. Although most direct reprogramming methods employ forced transduction of a defined sets of transcription factors to reprogram cells in a manner similar to induced pluripotent cell technology, many other strategies, such as methods utilizing chemical compounds and microRNAs to change the fate of somatic cells, have also been developed. In this review, we summarize transcription factor-based reprogramming and various other reprogramming methods. Additionally, we describe the various industrial applications of direct reprogramming technologies.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
NeuronsHepatocytesMyocytes, CardiacAnimalsHumansRegenerative MedicineEpigenesis, GeneticCellular ReprogrammingCellular Reprogramming Techniques

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research